Last updated: March 3, 2026
What is NDC 46122-0166?
NDC 46122-0166 corresponds to Vyondys 53 (golodirsen), a drug approved for treating Duchenne muscular dystrophy (DMD) in certain patient populations. Approved by the FDA in December 2019, it is marketed by Sarepta Therapeutics. It is an antisense oligonucleotide designed to induce exon 53 skipping at the genetic level.
Market Overview
Demographic and Clinical Demand
- Target Population: Patients with DMD with a confirmed mutation amenable to exon 53 skipping.
- Estimated Patient Population: Approximately 200-300 US patients are eligible for this therapy, given the mutation-specific indication [1].
Competitive Landscape
-
Key Competitors:
- Vyondys 53 (golodirsen) – Sarepta
- Emflaza (deflazacort) – PTC Therapeutics
- Amondys 45 (casimersen) – Sarepta, for exon 45 skipping
- Etiplersen – For DMD, in clinical trials
-
Market Share:
- Vyondys 53 holds a niche segment within DMD treatments, primarily competing with other exon-skipping therapies and corticosteroids.
Approval and Orphan Designation
- Approved under accelerated pathways, enabling competitive exclusivity.
- Market exclusivity likely lasts until at least 2024-2025, barring patent challenges.
Pricing Analysis
Current Pricing
- List Price: Approximately $350,000 to $400,000 per year per patient in the US [2].
- Pricing Context:
- Prices align with other exon-skipping therapies such as Amondys 45.
- Payers often negotiate discounts; actual reimbursed prices tend to be 10-25% lower.
Cost Factors and Reimbursement Dynamics
- Reimbursement: Usually via Medicare, Medicaid, and private insurers.
- Patient Assistance Programs: Sarepta offers programs to offset out-of-pocket costs.
- Pricing Trends:
- No significant recent price reductions.
- Growth in demand from increasing diagnosis rates and expanded indications.
Price Projections (2023-2028)
| Year |
Estimated Price Range |
Factors Influencing Price |
Notes |
| 2023 |
$340,000 – $400,000 |
Inflation, demand, payer negotiations |
Current observed prices |
| 2024 |
$340,000 – $410,000 |
Competition, market entry of new therapies |
Slight upward adjustment |
| 2025 |
$350,000 – $420,000 |
Potential patent exclusivity extensions |
Price stabilization expected |
| 2026 |
$350,000 – $425,000 |
Generic or biosimilar entry unlikely |
Market dynamics remain stable |
| 2027 |
$355,000 – $430,000 |
Increased diagnosis & approval of additional mutations |
Slight increase anticipated |
Note: Prices are subject to payer negotiations and possible downward adjustments due to discounts or changes in reimbursement policies.
Market Drivers and Risks
Drivers
- Increased diagnosis of DMD due to better genetic screening.
- Expanded indications for exon 53 skipping.
- Continued therapy development, including gene editing and other exon-skipping therapies.
Risks
- Competition from emerging therapies.
- Regulatory changes impacting drug pricing and reimbursement.
- Market saturation as more exon-skipping options receive approval.
Key Takeaways
- NDC 46122-0166 (Vyondys 53) primarily serves a niche within the DMD treatment landscape.
- Current US list prices hover around $350,000–$400,000 annually.
- Future prices are likely to stabilize due to market exclusivity and limited competition but may increase slightly with demand growth.
- Payer negotiations significantly influence actual reimbursement levels, often leading to discounts.
- The market's growth hinges on diagnosis rates, therapy adoption, and pipeline developments.
FAQs
Q1: How many patients are eligible for Vyondys 53?
Approximately 200-300 US patients with DMD carry mutations suitable for exon 53 skipping.
Q2: How does the pricing compare to other DMD treatments?
Vyondys 53's list price aligns with other exon-skipping therapies, around $350,000–$400,000 annually.
Q3: What factors could influence future prices?
Market competition, demand growth, patent protections, and reimbursement policies.
Q4: Are there alternative therapies in development?
Yes. Several exon-specific therapies and gene editing approaches are in clinical or preclinical stages.
Q5: What is the major risk to market share?
Emergence of new therapies, biosimilars, or changes in reimbursement policies could reduce market share.
References
[1] FDA. (2019). FDA approves Sarepta’s Vyondys 53 for Duchenne muscular dystrophy.
[2] GoodRx. (2023). Vyondys 53 pricing and discounts.
[3] Market Research Future. (2022). DMD market analysis.
[4] IQVIA. (2023). US prescription drug data.
[5] Sarepta Therapeutics. (2022). Vyondys 53 prescribing information.
